Callisto’s Guanilib Development Program is focused on a drug, Guanilib, to treat gastrointestinal (GI) inflammatory diseases. Callisto’s patented technology covers the development of agonists that are superior to uroguanylin, a peptide normally produced in the human intestinal tract.  Callisto’s lead drug candidate in this area, Guanilib, has demonstrated superior biological activity, enhanced stability and superior pH characteristics.  Guanilib is currently undergoing pre-clinical animal model studies as a treatment for GI inflammation in collaboration with clinical gastroenterologist Dr. Scott Plevy of the University of North Carolina, and the Company plans to file an investigational new drug (IND) application to treat ulcerative colitis.